PHARMACY MARKET

Yangtze River Pharmaceutical Group Selects TraceLink Platform for Global Compliance

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, including the United States and Europe.

"As we approach our 50th anniversary this year, we are preparing to deliver our innovations to global markets beyond China," said Mr. Luo Bai Gui GM's Executive Assistant, International Projects from YRPG. "Given the broad scope of our portfolio and diverse business model, TraceLink' s integrated network, global compliance solutions and low total cost of ownership are crucial for us to achieve commercial success in multiple markets."

"Global commercialization has become a top priority during this special milestone year for YRPG and serialization compliance is a necessary step in their preparation for global expansion," said Shabbir Dahod, President and CEO, TraceLink. "As one of the top pharmaceutical enterprises in China, YRPG is highly esteemed for its relentless innovation and TraceLink is proud to be their serialization partner of record as they embark on their journey of continued global growth."

With more than 16,000 employees and over 20 subsidiaries located across China, YRPG has established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCMs) and biological medicines. Yangtze River Pharmaceutical Group's products include Chinese, Western medicines and APIs, covering ten fields, nearly 20 dosage forms and over 300 types of medicines and strengths. Nearly 100 innovative drugs for major diseases are currently under research & development.

About Yangtze River Pharmaceutical Group
With a total manufacturing footprint of more than 3 million square meters, Yangtze River Pharmaceutical Group employs 16,000 and owns 11 manufacturing subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou, etc. The company fields established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCM) and biological medicines. Currently, Yangtze River Pharmaceutical Group exports part of its portfolio assortment to 30 countries including Europe, Asia and Africa.

About TraceLink
TraceLink is the only business network creation platform for building integrated business ecosystems with multienterprise applications. Business networks are the foundation of an Industry 4.0 digitalization strategy that delivers customer-centric agility and resiliency of the end-to-end supply network leveraging the collective intelligence of an industry. TraceLink's Opus Digital Network Platform enables speed of open innovation and implementation with a partner ecosystem for no-code and low-code development of solutions and applications.

Spotlight

Medical provider fraud is a multi-billion-dollar problem that continues to grow in both numbers and complexity as organized rings devise more intricate schemes to take advantage of Auto and Workers’ Comp carriers. Learn how LexisNexis® Claims Medical Discovery helps carriers identify potentially fraudulent medical provider behavior by resolving provider identities, revealing anomalous patterns and utilizing analytics to monitor suspect providers.

Spotlight

Medical provider fraud is a multi-billion-dollar problem that continues to grow in both numbers and complexity as organized rings devise more intricate schemes to take advantage of Auto and Workers’ Comp carriers. Learn how LexisNexis® Claims Medical Discovery helps carriers identify potentially fraudulent medical provider behavior by resolving provider identities, revealing anomalous patterns and utilizing analytics to monitor suspect providers.

Related News

BUSINESS INSIGHTS

FGC Health Expands Solutions Offerings With Acquisition of Pharmacy Access Solutions Inc (PASI)

FGC Health | March 04, 2022

FGC Health, a national leader in consumer health services, industry-specific business tools and provider of an industry-leading proprietary open-source platform, announced today it has acquired Pharmacy Access Solutions Inc. (PASI), an industry leader in the development of real-time, smart technology solutions in support of automated patient-centric programs and professional service modules, as well as financial and performance reporting for independent owners and banner groups. PASI will continue to operate as a standalone organization. FGC Health has acquired the entirety of PASI and its business for $4 million USD, and will begin integrating PASI’s solutions into its own industry-leading proprietary open-source platform, to further strengthen its own solutions’ capabilities, offering an end-to-end suite of business tools for the healthcare industry. “Our goal has always been to provide a complete suite of industry-specific business tools for businesses of all kinds within the Canadian healthcare system, and with today’s announcement, we are very excited to be able to bring the power of PASI’s solutions onto our platform, with the purpose of empowering independent pharmacies to thrive in a very competitive market. As a business who has served the Canadian healthcare industry for 20 years, PASI also brings with them a team with a deep well of industry knowledge and a shining track record of bringing excellence and innovation to the retail pharmacy industry, and we look forward to everything our businesses will be able to achieve together for Canadian healthcare providers in the future.” Dalbir Bains, CEO of FCG Health PASI’s software solutions include real-time automation capabilities, as well as a unique, cost-effective, and scalable “middleware” conduit, and centralized cloud-based data solution, allowing proprietary integration capability across multiple software and data platforms, including but not limited to Pharmacy Management Systems, Point of Sale Systems, Electronic Medical Records, and Financial Accounting Software, designed with the objective of improving operational efficiencies for independent retail pharmacy. About FGC Health FGC connects your health care business to FGC’s proprietary open-source platform. This connected platform enables health care professionals to practice at the top of their license along with providing a more connected and engaging experience for its patients. FGC owns, operates, and services independent pharmacies, medical clinics, home health care and ambulatory care services. Please visit www.fgchealth.com to learn more about the company and its software offerings. About Pharmacy Access Solutions Inc. Pharmacy Access Solutions Inc. (PASI) is an industry leader in the development of real-time, smart technology solutions that efficiently and effectively support the implementation of patient-centric programs and professional services within the pharmacist’s expanded scope of practice. .

Read More

PHARMACY MARKET

Aizon Launches GxP AI Bioreactor Application for the Pharma Industry

Aizon | February 02, 2021

Aizon launches its Bioreactor Application, the pharma industry's first predictive analysis and profound knowledge management application. The Aizon Bioreactor Application adds the bioreactor process to the "Smart Manufacturing" transformation that is accelerating across the Pharma and Biotech industry. Aizon is extraordinarily able to achieve GxP compliance and give an audit trail from the start of the process. The turnkey application allows pharmaceutical and biotech companies to leverage rich datasets generated during upstream manufacturing to identify and accurately anticipate deviations and results potentially leading to countless dollars in expense savings, diminished danger, and additional income potential gain. Intended to work with both persistent and took care of batch bioreactors, the Aizon Bioreactor Application gives a profound understanding of the client's bioprocess manufacturing lifecycle. The application leverages specialized Edge AI and contextualization, which is a prerequisite to make the data actionable. Contextualized data is harnessed, analyzed, and visualized through a persona-based lens for faster root cause analysis (RCA), real-time monitoring, and predictive insight across any number of bioreactor units and manufacturing sites. AI models for bioreactor analytics are ready for use within the application or can be configured by customers within the GxP cloud-based application. “It is clear that biotech and pharmaceutical companies need an accessible, industry-specific tool that accelerates their path to value. Customers seek a seamless way to analyze complex data sets in real-time and to predict with accuracy the yield from bioreactor units that span multiple sites and global regions,” said Pep Gubau, CTO, Aizon. “Biotech and pharmaceutical companies can now more easily leverage the power of AI/ML in a GxP environment with an end-to-end lifecycle governance of data, models, and applications in order to understand and optimize bioreactor processes in commercial manufacturing.” Aizon’s CEO, John Vitalie adds, ”Our focus is to empower customers to innovate and rapidly achieve their targeted outcomes without the overhead burden of tracking changes, revalidation, and on-going development to maintain compliance. By building the process knowledge framework, compliance, and scalability into the application, customers benefit significantly from the streamlined industrialization of their digital solutions. We see that this is key for pharma and biotech to realize the vision of smart manufacturing and accelerate their progress toward realizing the promise of the adaptive plant.” About Aizon Aizon is an enterprise software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within Pharma and other highly regulated industries. The Aizon AI platform and native GxP based applications seamlessly integrate unlimited sources of structured and unstructured data to deliver actionable, real-time insights across all manufacturing sites. Aizon brings deep domain expertise and works closely with Global System Integrators and technology partners to provide enterprise solutions to customers.

Read More

BUSINESS INSIGHTS

To Provide Suite of Clinical Trial Technologies and Services, Labcorp Renewed Strategic Partnership with Medidata

Medidata | April 01, 2022

A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentralized clinical trial offerings. Our work to advance sensor and digital biomarker usage in clinical research can help accelerate patient care while providing valuable information to study sponsors.” Bill Hanlon, Ph.D., chief scientific officer and president of Clinical Therapeutic and Regulatory Sciences, Labcorp Drug Development Labcorp Drug Development's products are based on Medidata technology, including Rave EDC, Coder, and TSDV. In addition, Labcorp is currently using most of the Medidata Clinical Cloud platform, including eCOA, RTSM, and Imaging. “The last two years have required clinical trials to become more accessible and flexible; these changes make our strategic partnership with Labcorp Drug Development to modernize and decentralize trials even more critical,” said Anthony Costello, CEO Patient Cloud at Medidata. “With this new agreement, we’re excited to develop and deploy the innovations that help our customers run more effective clinical programs and get new treatments to patients faster than ever before.” Through its 3DEXPERIENCE platform, Medidata is positioned to lead the digital transformation of life sciences in the era of personalized medicine by providing the industry's first end-to-end scientific and business platform, from research to commercialization.

Read More